Sugi Predict

Sugi Predict / Compounds / SCHEMBL4771971

SCHEMBL4771971

SCHEMBL4771971

CC(C)(C)OC(=O)N1CCC(c2c[nH]c3cc(Cl)ccc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AVPR1A P37288 1/20 0.50
▸ CNR1 P21554 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ BRD4 O60885 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ CREBBP Q92793 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ MAPT P10636 2/20 0.48
▸ THRB P10828 1/20 0.48
▸ SLC6A4 P31645 1/20 0.47
▸ CCR2 P41597 1/20 0.47
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ USP2 O75604 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ STS P08842 2/20 0.46
▸ JAK2 O60674 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30567991 0.91 OPRM1 (0.53) CNR1KDM4EBRD4ALDH1A1POLB
SCHEMBL892836 0.91 OPRM1 (0.53) CNR1KDM4EBRD4ALDH1A1POLB
Hydrochloric Acid SCHEMBL1703941 0.90 OPRM1 (0.52) CNR1KDM4EBRD4ALDH1A1POLB
SCHEMBL12127425 0.87 KDM4E (0.49) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL4882143 0.87 DRD2 (0.56) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL22491591 0.85 KDM4E (0.45) CNR1KDM4EBRD4ALDH1A1POLB
SCHEMBL557776 0.84 KDM4E (0.70) KDM4EBRD4ALDH1A1POLBCREBBP
SCHEMBL16801526 0.84 KDM4E (0.69) AVPR1AKDM4EBRD4ALDH1A1POLB
SCHEMBL28097373 0.83 SLC6A4 (0.48) AVPR1AKDM4EBRD4ALDH1A1POLB
Hydrochloric Acid SCHEMBL1703924 0.83 KDM4E (0.68) KDM4EBRD4ALDH1A1POLBCREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2026-05-28 — — US disclosed
EP-4605395-A2 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS Dong-A ST Co., Ltd. (KR) 2025-08-27 — — EP disclosed
WO-2024084448-A2 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS DONG-A ST CO., LTD. (KR) 2024-04-25 — — WO disclosed
US-11420961-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2022-08-23 — — US disclosed
EP-3717477-B1 NEW HETEROCYCLIC COMPOUNDS HOFFMANN LA ROCHE (CH) 2022-07-20 — — EP disclosed
US-20200392125-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2020-12-17 — — US disclosed
EP-3717477-A1 NEW HETEROCYCLIC COMPOUNDS H. Hoffnabb-La Roche Ag (CH) 2020-10-07 — — EP disclosed
CN-111386269-A Novel heterocyclic compound 豪夫迈·罗氏有限公司 2020-07-07 — — CN disclosed
CN-106045967-B Substituted heterocyclic compounds and their use in medicine 广东东阳光药业有限公司 2020-04-21 — — CN disclosed
CN-106045966-B Substituted heterocyclic compounds and their use in medicine 广东东阳光药业有限公司 2020-04-21 — — CN disclosed
US-20030225063-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-12-04 — — US disclosed
US-6635633-B2 Substituted pyrazoles ORTHO-PHARMACEUTICAL, INC. 2003-10-21 — — US disclosed
WO-2003076398-A2 PYRROLE-2, 5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS ELI LILLY AND COMPANY (US) 2003-09-18 — — WO disclosed
US-6579896-B2 Immunology response; autoimmune disease ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-06-17 — — US disclosed
EP-1315492-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES Ortho McNeil Pharmaceutical, Inc. (US) 2003-06-04 — — EP disclosed
EP-1309592-A2 SUBSTITUTED PYRAZOLES Ortho-McNeil Pharmaceutical, Inc. (US) 2003-05-14 — — EP disclosed
US-20020147189-A1 Method for treating allergies using substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2002-10-10 — — US disclosed
US-20020040019-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2002-04-04 — — US disclosed
WO-2002020013-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-03-14 — — WO disclosed
WO-2002014317-A2 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040019-A1 Substituted pyrazoles CTSS, CTSZ, CTSV AVPR1A 4825/4885CNR1 2781/4885KDM4E 2928/4885
US-20030225063-A1 Substituted pyrazoles CTSS, CTSZ, CTSV AVPR1A 4825/4885CNR1 2781/4885KDM4E 2928/4885
US-11420961-B2 Heterocyclic compounds LPXN, MLX, CCNY AVPR1A 916/4885CNR1 295/4885KDM4E 1597/4885
US-20260146035-A1 FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS AXL, ERBB2, ERBB3 AVPR1A 3120/4885CNR1 294/4885KDM4E 2438/4885
US-20020147189-A1 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 AVPR1A 4370/4885CNR1 1796/4885KDM4E 2491/4885
US-20200392125-A1 HETEROCYCLIC COMPOUNDS LPXN, MLX, CCNY AVPR1A 916/4885CNR1 295/4885KDM4E 1597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.